Navigation Links
Duska Therapeutics Provides Program Update and Reports Third Quarter 2008 Financial Results
Date:11/20/2008

LA JOLLA, Calif., Nov. 20 /PRNewswire-FirstCall/ -- Duska Therapeutics, Inc. (OTC Bulletin Board: DSKA) will host a teleconference call today at 2:30 p.m. EST to review its drug development programs and financial results for the third quarter of 2008. Duska's chief executive officer, James S. Kuo, MD, MBA, will host the call and there will be a question-and-answer session immediately afterward.

To participate in the teleconference, please call toll-free 800.895.0198 (direct dial 785.424.1053) five minutes prior to the scheduled starting time in order to register for the call. A replay of the call will be available after its completion for ten days at 800.283.8217 (direct dial 402.220.0868).

"We have made remarkable progress in our two lead drug development programs this past quarter as we prepare for a Phase 2 trial for one compound and a Phase 3 trial for the other early next year," said Dr. Kuo. "In addition, we strengthened the intellectual property position around our ATPotent program through licenses with several inventors."

    Highlights of accomplishments included:

    -- Submission of a pivotal Phase 3 ATPace clinical trial protocol for
       review under a Special Protocol Assessment (SPA) procedure with the
       U.S. Food and Drug Administration (FDA).

       Subject to securing an agreement with the FDA, Duska intends to
       initiate a single, prospective, double-blind, placebo-controlled and
       randomized Phase 3 clinical trial with ATPace, its lead product. The
       trial will be aimed at demonstrating clinical safety and efficacy of
       ATPace in treating emergency room patients presenting with paroxysmal
       supraventricular tachycardia (PSVT).  PSVT is a condition characterized
       by a rapid, regular heart rate originating in the atria, which affects
       approximately 570,000 patients in the United States alone; in addition,
       89,000 new cases per 
'/>"/>
SOURCE Duska Therapeutics, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related biology technology :

1. Leading Heart Specialist Joins Duska Therapeutics as Scientific Consultant
2. Duska Therapeutics to Present at Noble Financial Equity M.A.D. MAX Conference on Tuesday, August 19th at 1:30 p.m. PDT
3. Duska Therapeutics Submits Phase 3 ATPace(TM) Protocol to FDA for Comment
4. Duska Therapeutics Obtains Standard & Poors Listing
5. Synvista Therapeutics Announces 510(k) Submission for Its HAPTOCHEK(TM) Test Kit
6. Arete Therapeutics Closes $16.7 Million in Final Tranche of Its Series A Financing
7. TorreyPines Therapeutics Appoints Evelyn Graham Chief Executive Officer and a Member of the Board of Directors
8. TorreyPines Therapeutics Reports Third Quarter 2008 Results and Recent Accomplishments
9. Synvista Therapeutics Announces Data Further Demonstrating the Value of Haptoglobin Genotyping in Diabetic Patients During AHA Meeting
10. Amicus Therapeutics to Present at Lazard Capital Markets Healthcare Conference
11. Synvista Therapeutics to Present at the Rodman & Renshaw 10th Annual Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/14/2014)... protein functions in a wide variety of ways, including ... protein can take on another form and perform no ... fold wrongly can cause serious diseases such as Alzheimer,s, ... have a tendency to "infect" other molecules of the ... or plaques. These amyloids can damage cells and tissues ...
(Date:9/12/2014)... Switching the polarity of a magnet using an ... a working principle of the next-generation technology for ... candidates for the MEM effect, due to the ... other hand, the coexistence of spontaneous electric and ... hinders the application potential of the MEM effect. ...
(Date:9/12/2014)... 2014 Research and Markets has ... Photoresist Industry Report 2014" report to their offering. ... Report 2014 is a professional and in-depth study on ... industry . The report provides a basic ... industry chain structure. The dry film photoresist market analysis ...
(Date:9/12/2014)... NM (PRWEB) September 12, 2014 Sandia ... an exclusive option agreement with STC.UNM (STC) for a ... Mexico (UNM) in Albuquerque, New Mexico, and Queen Mary ... of technologies, called the Recombinant Fluorescent Antibody Technology Platform ... Department of Internal Medicine and Dr. Angray Kang from ...
Breaking Biology Technology:Measuring modified protein structures 2Measuring modified protein structures 3Global Dry Film Photoresist Industry Report 2014 2Sandia Biotech and STC.UNM Announce Option Agreement to License Novel Recombinant Antibody Technology 2Sandia Biotech and STC.UNM Announce Option Agreement to License Novel Recombinant Antibody Technology 3Sandia Biotech and STC.UNM Announce Option Agreement to License Novel Recombinant Antibody Technology 4
... the casual observer, responders contained the recent E. coli ... health professionals, the automated system used to identify the ... improvement. , ,Still, information technology played a key role ... and it will play an even greater role in ...
... about your firm? Slow? Fast? Lightning Speed? Not sure? , ... yet to adopt a wiki. A wiki, you ask, what's that? ... Today, it has come to mean a collaborative and group editable ... 2.0 that encourage conversations and draw on the power of social ...
... of change sparked by the information technology industry gives ... business challenge, but has IT really come through for ... recent Wisconsin technology conference, the results are mixed but ... Systems , brought together more than 300 corporate clients ...
Cached Biology Technology:Technology played key role in E. coli alerts 2Technology played key role in E. coli alerts 3Technology played key role in E. coli alerts 4Joining the wiki wacki world 2Joining the wiki wacki world 3Joining the wiki wacki world 4Joining the wiki wacki world 5Are businesses getting what they need from IT? 2Are businesses getting what they need from IT? 3
(Date:9/15/2014)... This news release is available in German . ... of a cell is straightforward: it doubles, divides in ... it has been long assumed that cells of the ... divide symmetrically. Silvia Bulgheresi,s team, University of Vienna, revealed ... long to be perceivable by the naked eye. These ...
(Date:9/15/2014)... in our cells cooperate with one another. But, it ... of different proteins find the correct dancing partners as ... and nervous system. A recent breakthrough at the University ... door and provided a look at the once obscure ... Jens Jrgen Led of the University of Copenhagen,s Department ...
(Date:9/15/2014)... tropical rainforest teeming with life it,s not what comes ... the first time evidence of Doncaster,s 310-million-year-old past, including a ... mining tip. , Some of the fossilised plants and creatures ... the egg case, several horseshoe crabs and some previously unrecorded ... preserved in rocks that formed within the coal and shale ...
Breaking Biology News(10 mins):Think big! Bacteria breach cell division size limit 2Protein courtship revealed through chemist's lens 2Protein courtship revealed through chemist's lens 3'Jaws' lived in Doncaster 2
... University researcher is studying whether the most popular ... in users. There is accumulating evidence that ... including muscle weakness, fatigue and deterioration ... radiology and osteopathic manipulative medicine at MSU. ...
... by a team of scientists using optical probes means ... now be seen in a completely different light. ... working with experts from Glasgow University, and a team ... the way that light was emitted by optical probes ...
... worldwide decline in the number of bees and other ... yields, according to the results of an international study ... journal, Current Biology . , Co-author, CSIRO ... detected warning signs that demand for pollinators is still ...
Cached Biology News:MSU researcher studies ties between cholesterol drugs, muscle problems 2Luminescence shines new light on proteins 2Pollinator decline not reducing crop yields just yet 2
Modified and insect cell culture tested....
BD BaculoGold Max-XP Insect Cell Medium 1 Liter...
Mycoplasma and virus tested...
Bethyl Laboratories Ready-To-Use IHC Bluing Reagent is used following IHC hematoxylin counterstaining with immunohistochemical procedures. Shelf-Life: 1 year from date of receipt...
Biology Products: